计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Moligand™ 级 提供 ≥97% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Information
Nazartinib (EGF816, NVS-816) is a covalent, irreversible, mutant-selectiveEGFRinhibitor that has nanomolar inhibitory potency against activating mt (L858R, ex19del) and T790M mt, with up to 60-fold selectivity over wild type (wt) EGFR in vitro.
Targets
mutant EGFR 0.031 μM(Ki)
In vitro
EGF816 is a novel, covalent, mutant-selective EGFR inhibitor with nearly equipotent activity on both oncogenic (L858R and ex19del) and T790M-resistant mutations and good selectivity over WT EGFR. EGF816 potently inhibits the most common EGFR mutations L858R, Ex19del, and T790M in vitro. The cellular activity of EGF816 on EGFR mutants are assessed using three well-characterized cell lines, H3255, HCC827, and H1975, which harbor the L858R, Ex19del, and L858R/T790M mutations, respectively. After incubation with cells for 3 hours, EGF816 shows potent inhibition of pEGFR levels in H3255, HCC827, and H1975 with EC50 values of 5, 1, and 3 nmol/L, respectively. Cellular-based assays shows that EGF816 is selective toward mutant over WT EGFR.
In vivo
EGF816 is well tolerated and possesses favorable physicochemical properties and good oral bioavailability in mice. It shows moderate volume of distribution and low to moderate clearance in rodents (30% and 35% of rat and mouse liver blood flow, respectively). In the dog, EGF816 shows high clearance and high volume of distribution. EGF816 also demonstrates antitumor activity in an exon 20 insertion mutant model. At levels above efficacious doses, EGF816 treatment leads to minimal inhibition of WT EGFR and is well tolerated. In single-dose studies, EGF816 provides sustained inhibition of EGFR phosphorylation, consistent with its ability for irreversible binding. EGF816 has a longer half-life in human than mouse and is currently being evaluated in phase I/II clinical trials in patients harboring EGFR mutations, including T790M.
Cell Research(from reference)
Cell lines:H1975, H3255, HCC827, A431, and HaCaT cells
Incubation Time:3 h
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 有机杂环化合物 |
| 类(Class) | 苯并咪唑类 |
| 亚类(Subclass) | 暂无 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 苯并咪唑类 |
| 其他上位类(Alternative Parents) | 吡啶甲酰胺 氮杂环庚烷 甲基吡啶 N-取代咪唑 芳基氯化物 苯类化合物 杂芳族化合物 叔羧酸酰胺 三烷基胺 氨基酸及其衍生物 仲羧酸酰胺 氮杂环化合物 有机氯化物 有机氧化物 碳氢化合物衍生物 羰基化合物 |
| 分子骨架(Molecular Framework) | 芳香族杂多环化合物 |
| 取代基(Substituents) | 氨基酸 - 氨基酸或其衍生物 - 芳香族杂多环化合物 - 芳基氯化物 - 芳基卤化物 - 氮杂环 - 氮杂环戊烷 - 吡唑 - 苯基化合物 - 苯并咪唑 - 羰基 - 羧酰胺基 - 羧酸衍生物 - 杂芳香族化合物 - 烃衍生物 - 咪唑 - 甲基吡啶 - N-取代咪唑 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机氯化物 - 有机卤化物 - 有机氮化合物 - 有机氧化合物 - 吡啶 - 吡啶羧酸或其衍生物 - 吡啶甲酰胺 - 醛基 - 三元脂肪胺 - 三芳基胺 - 叔羧酸酰胺 |
| 描述(Description) | 该化合物属于苯并咪唑类有机化合物。这类化合物含有苯环与咪唑环(含氮原子、4个碳原子及两个双键的五元环)共轭的结构。 |
| 外部描述符(External Descriptors) | 暂无 |
| IC50 | mutant EGFR, Ki: 0.031 μM |
|---|---|
| ALogP | 3.705 |
| hba_count | 4 |
| HBD Count | 1 |
| Rotatable Bond | 6 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | N413844 | |
| 分析证书 | N413844 | |
| 分析证书 | N413844 | |
| 分析证书 | N413844 | |
| 分析证书 | N413844 | |
| 分析证书 | N413844 | |
| 分析证书 | N413844 | |
| 分析证书 | N413844 | |
| 分析证书 | N413844 | |
| 分析证书 | N413844 |